Synlogic Inc · OTC:SYBX
Synlogic — Q2 2020 Earnings Presentation
16 slides from Synlogic's earnings presentation, Aug 6, 2020
Slide 1: Designed For Life: Q2 Financial Results & Business Update
Designed For Life Q2 Financial Results & Business Update 6 August 2020 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Opening Remarks
© 2019 SYNLOGIC. ALL RIGHTS RESERVED. | Opening Remarks Dr. Aoife Brennan MB CHB President & CEO
Slide 4: 2nd Quarter Highlights
Julia, living with PKU 2nd Quarter Highlights We are building the premier Synthetic Biology platform to engineer bacterial Synthetic Biotic medicines that benefit patients in new ways Team, technology and portfolio to succeed: appointed Antoine Awad as COO Rapidly progressed metabolic programs SYNB1
Slide 5: Advancing The Pipeline
Advancing The Pipeline Emerging treatment options in PKU will continue to leave many patients behind SYNB1618 demonstrates potential to lower Phe in PKU patients Phase 2 Phe -lowering trial starting in 2H 2020 Next generation strain in development
Slide 6: Advancing The Pipeline
Advancing The Pipeline SYNB1891 (Synthetic Biotic for intratumoral injection) continues to enroll monotherapy cohorts SYNB1891 will provide clinical data from monotherapy cohorts in 2020 SYNB1891 has potential for improved efficacy relative to other STING approaches Emerging treatment options in PKU
Slide 7: Upcoming Milestones
Upcoming Milestones Expected Milestone 2020 2021 early mid late early mid late SYNB1618 PKU Initiate Ph.2 study in PKU patients Ph.2 Phe-lowering read-out SYNB8802 HOX Initiate IND-enabling studies initiated Initiate Ph.1 study in HV and Patients Ph.1 Patient Read-out SYNB1891 I/O Ph.1 Monotherapy r
Slide 8: 2nd Quarter 2020 Summary Results
Julia, living with PKU 2nd Quarter 2020 Summary Results Strong Cash Position With Runway Into 2022 Balance Sheet (unaudited) 30 June 2020 31 Mar 2020 Cash, Cash Equivalents, and Short & Long Term Marketable Securities $109.1M $114.3 M Statement of Operations (unaudited) 30 June 2020 30 June 2019 R&D
Slide 9: Focus On Enteric Hyperoxaluria
Focus On Enteric Hyperoxaluria Dr. Richard Riese, MD, PhD Chief Medical Officer
Slide 10: Enteric Hyperoxaluria: Overview
Enteric Hyperoxaluria: Overview Dietary Sources of Oxalate Risk Factors IBD Roux-en-Y Gastric Bypass Short Bowel Syndrome Chronic Pancreatitis Clinical Manifestations Nephrocalcinosis, Stones, and Risk of Chronic Kidney Disease Dietary Sources of Oxalate Are Difficult To Avoid, Putting Patients at R
Slide 11: Hyperoxaluria: Primary vs. Enteric
Hyperoxaluria: Primary vs. Enteric Number of Patients Affected Primary Hyperoxaluria Enteric Hyperoxaluria Pathology Family of autosomal recessive monogenic disorders in which liver enzyme deficiency results in endogenous oxalate overproduction Pathogenic hyperabsorption of dietary oxalate, often ac
Slide 12: SYNB8802 Poised To Enter The Clinic
SYNB8802 Poised To Enter The Clinic * Tasian GE, Poster SA-PO276; Kidney Week 2019 Enteric Hyperoxaluria manifests in dangerously high urinary oxalate levels, putting patients with pre-existing bowel disease at 3-4x higher risk of CKD * Differentiated profile - engineered to absorb oxalate from thro
Slide 13: Enteric Hyperoxaluria: Our Next Step To Synthetic Biotic Medicines
Enteric Hyperoxaluria Our Next Step To Synthetic Biotic Medicines High unmet medical need with no available therapeutic options Efficient clinical development: PoC achievable in Phase 1b SYNB8802 has potential to meaningfully reduce urinary oxalate levels
Slide 14: Concluding Remarks
© 2019 SYNLOGIC. ALL RIGHTS RESERVED. | Concluding Remarks Dr. Aoife Brennan MD CHB President & CEO
Slide 15: Available For Questions
Available For Questions Aoife Brennan, MD CHB President & CEO Richard Riese, MD PhD CMO Gregg Beloff, JD MBA Interim CFO Antoine Awad COO
Slide 16: Synlogic contact details
301 BINNEY ST., #402, CAMBRIDGE, MA 02142 TEL: 617-401-9975 WEB: WWW.SYNLOGICTX.COM EMAIL: INFO@SYNLOGICTX.COM © SYNLOGIC. ALL RIGHTS RESERVED.